Meyahealth
Home
ENES
HomeGeneticsGeneKLF1 gene
Back to Gene

KLF1 gene

Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

KLF1 gene

The KLF1 gene encodes a transcription factor that regulates the development of red blood cells and the production of hemoglobin.

Normal Function

The KLF1 gene provides instructions for making a protein that acts as a transcription factor, attaching to specific regions of DNA to control the activity of particular genes. Specifically, the KLF1 protein regulates the final stages of red blood cell development (erythropoiesis).

This protein plays an important role in the production of hemoglobin, which carries oxygen throughout the body. During development, the KLF1 protein regulates the switch from the production of fetal hemoglobin to the adult form of hemoglobin.

Health Conditions Related to Genetic Changes

Congenital dyserythropoietic anemia

A variant in the KLF1 gene has been identified in people with congenital dyserythropoietic anemia (CDA) type IV. This condition is characterized by a shortage of red blood cells caused by abnormal red blood cell formation.

  • In people with CDA type IV, immature red blood cells (erythroblasts) are unusually shaped, may have more than one nucleus, and cannot develop into functional, mature cells.
  • This leads to symptoms such as weakness, an enlarged liver and spleen (hepatosplenomegaly), iron overload, and short stature.
  • The KLF1 variant reduces protein function and disrupts the regulation of genes involved in red blood cell development.
  • Affected individuals often produce higher than normal levels of fetal hemoglobin throughout their lives.

Genomic Location

The KLF1 gene is found on chromosome 19.

Frequently Asked Questions

KLF1 variant impairs the transcription factor that drives red blood cell maturation, causing immature erythroblasts to be abnormally shaped, sometimes multinucleated, and unable to mature. Clinically, patients present with chronic anemia, fatigue, pallor, and often an enlarged liver and spleen (hepatosplenomegaly). Iron overload can develop due to increased absorption, and patients may also have short stature and mild jaundice. The hallmark is a persistent low red blood cell count despite normal or elevated reticulocyte production.
Initial workup includes a complete blood count, peripheral smear, and iron studies. If red cell morphology is abnormal and other causes are excluded, a bone marrow aspirate may show dysplastic erythroid precursors. Genetic confirmation requires sequencing of the KLF1 gene—often through a targeted hemoglobinopathy panel or whole‑exome sequencing—to identify pathogenic variants. Genetic counseling is recommended for affected families.
Management focuses on treating anemia and preventing iron overload. Regular blood transfusions may be needed for severe anemia, but they increase iron load, so iron chelation therapy (e.g., deferasirox) is often started early. Splenectomy can reduce hemolysis in some patients, but carries infection risk. Because KLF1 mutations also raise fetal hemoglobin, therapies that further increase HbF (like hydroxyurea) can be considered, though evidence is limited. Close monitoring of hemoglobin, iron levels, and organ function is essential.
Yes, many KLF1 variants lead to persistently elevated fetal hemoglobin (HbF) throughout life. Higher HbF can partially compensate for defective adult hemoglobin, reducing anemia severity. This knowledge can guide treatment: clinicians may favor strategies that maintain or boost HbF (e.g., hydroxyurea or newer agents like Luspatercept) rather than aggressive transfusion protocols. Additionally, the elevated HbF may reduce the need for iron chelation if anemia is milder, but each patient’s iron status must still be monitored closely.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.